We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Says PDUFA VII Should Address Rise in Cell and Gene Therapies
FDA Says PDUFA VII Should Address Rise in Cell and Gene Therapies
The FDA plans to channel more resources to the Center for Biologics Evaluation and Research (CBER)’s Cell and Gene Therapy Program (CGTP) to deal with its rapidly growing workload, agency officials said at the first round of public meetings on the next reauthorization of the Prescription Drug User Fee Act (PDUFA).